Clinical Research Directory

Inclusion Criteria: For the 110 patients with MPN: * Patients with PV, ET or PMF * DNA extracted from purified granulocytes at time of diagnosis * No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) For the 10 subjects without MPN: * Absence of hematological malignancy * Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia * Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) Exclusion Criteria: For the 110 patients with MPN: * Patients without PV, ET or PMF * Patients without purified granulocytes DNA available at time of diagnosis * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling * Patients with less than 2 years' follow-up For the 10 subjects in NMP : * Patients with hematological malignancy and/or solid cancer * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling